Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021
Shots:
- The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed- qd) vs vehicle (qd) in 1-025 patients aged 18-75yrs. with plaque psoriasis
- Results: 2EPs & PRO- @12wks.- PASI90 (18.8% and 20.9%) vs (1.6% and 2.5%)- ≥4-point NRS improvement (67.5% and 59.7%) vs (46.1 and 31.3%)- improvement in QoL as measured by the DLQI- ≥90% reduction in one in five patients in PASI90- improvements in itch measured with PP-NRS
- Tapinarof is a steroid-free- cosmetically elegant- TAMA topical cream for the treatment of PsO and AD. The data will be included in NDA submission- expected in mid-2021
Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com